Cervical cancer is the fourth most common cancer and the leading cause of cancer-related deaths in females worldwide. However, when diagnosed early, cervical cancer is highly treatable and can be successfully managed. Intracavitary brachytherapy (ICBT), interstitial brachytherapy (ISBT), and the combined intracavitary/interstitial brachytherapy (IC/ISBT) are versatile forms of internal radiation therapy providing local treatment to specific organs. Brachytherapy is now regarded as an essential treatment modality in many cancers, particularly locally advanced cervical cancer. It has demonstrated marked improvements in patient survival alongside external beam radiotherapy (EBRT) combined with concurrent platinum-based chemotherapy. However, there is still a need to outline potential acute side effects comprehensively, and the reduction of toxicity to adjacent organs at risk (OARs) for safe dose escalation is still a priority concern.
This Research Topic aims to provide insight into brachytherapy's usage, benefits, and challenges in cervical cancer. We welcome Original Research and Review articles focused by not limited to the following:
- The role and significance of brachytherapy in early-stage cervical cancer
- Current diagnostic methods to identify patients suitable for brachytherapy
- Technical advances in applicators, delivery, and planning to improve current standards of care
- Challenges associated with administration and delivery of brachytherapy
Cervical cancer is the fourth most common cancer and the leading cause of cancer-related deaths in females worldwide. However, when diagnosed early, cervical cancer is highly treatable and can be successfully managed. Intracavitary brachytherapy (ICBT), interstitial brachytherapy (ISBT), and the combined intracavitary/interstitial brachytherapy (IC/ISBT) are versatile forms of internal radiation therapy providing local treatment to specific organs. Brachytherapy is now regarded as an essential treatment modality in many cancers, particularly locally advanced cervical cancer. It has demonstrated marked improvements in patient survival alongside external beam radiotherapy (EBRT) combined with concurrent platinum-based chemotherapy. However, there is still a need to outline potential acute side effects comprehensively, and the reduction of toxicity to adjacent organs at risk (OARs) for safe dose escalation is still a priority concern.
This Research Topic aims to provide insight into brachytherapy's usage, benefits, and challenges in cervical cancer. We welcome Original Research and Review articles focused by not limited to the following:
- The role and significance of brachytherapy in early-stage cervical cancer
- Current diagnostic methods to identify patients suitable for brachytherapy
- Technical advances in applicators, delivery, and planning to improve current standards of care
- Challenges associated with administration and delivery of brachytherapy